Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories diagnostics — Remaining Performance Obligations / Long-Term Reagent & Instrument Backlog ($M) ($M)
Form 10-K / 10-Q Note (Revenue Recognition — Remaining Performance Obligations)
Latest, FY2025
6,100
Period ended Dec 31, 2025
Change on a year earlier
+10.9%
5,500 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Diagnostics — Remaining Performance Obligations / Long-Term Reagent & Instrument Backlog ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6,100 | +10.9% | SEC Filing (0001628280-26-010185) ↗ |
| FY2024 | Dec 31, 2024 | 5,500 | +25.0% | SEC Filing (0001628280-25-007110) ↗ |
| FY2023 | Dec 31, 2023 | 4,400 | +10.0% | SEC Filing (0001628280-24-005348) ↗ |
| FY2022 | Dec 31, 2022 | 4,000 | 0.0% | SEC Filing (0001628280-23-004026) ↗ |
| FY2021 | Dec 31, 2021 | 4,000 | +5.3% | SEC Filing (0001104659-22-025141) ↗ |
| FY2020 | Dec 31, 2020 | 3,800 | +15.2% | SEC Filing (0001104659-21-025751) ↗ |
| FY2019 | Dec 31, 2019 | 3,300 | +13.8% | SEC Filing (0001104659-20-023904) ↗ |
| FY2018 | Dec 31, 2018 | 2,900 | – | SEC Filing (0001047469-19-000624) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Diagnostics — Remaining Performance Obligations / Long-Term Reagent & Instrument Backlog ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-rpo
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.